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COST-EFFECTIVENESS ANALYSIS OF
SIMVASTATIN AND LOVASTATIN/EXTENDED-
RELEASE NIACIN TO ACHIEVE LDL AND HDL
GOAL USING NHANES DATA
Armstrong EP, Zachry III WM, Malone DC
University of Arizona,Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to investi-
gate the likelihood of achieving both LDL and HDL goals
in the primary prevention of cardiovascular disease using
an epidemiologic sample of United States residents by
comparing simvastatin to a combined regimen of lovas-
tatin/extended-release niacin. An additional objective was
to estimate the cost-effectiveness of each product and the
incremental cost-effectiveness ratio between regimens.
METHODS: A decision analytic model was developed to
compare the cost-effectiveness of simvastatin and lovas-
tatin/extended-release niacin. Product labeling estimated
the change in cholesterol concentrations and the fre-
quency of clinically important adverse events. The Third
National Health and Nutrition Examination Survey
(NHANES) adult data were used to estimate population
cholesterol levels. Average wholesale price was used for
medication costs. RESULTS: The NHANES data revealed
there were 256 patients (10.5%) that required a LDL goal
of <160mg/dL, 1268 (52.2%) that required a goal of
<130mg/dL, and 906 patients (37.3%) that required a
goal of <100mg/dL. For both the 130mg/dL and 100
mg/dL LDL goal analyses (and HDL ≥40mg/dL), lovas-
tatin/extended-release niacin had higher success rates and
lower average total costs than simvastatin. Simvastatin
had the highest success rate in achieving LDL level 
<160mg/dL and HDL ≥40mg/dL. However, the average
total health system cost (medications, physician visit
costs, and laboratory costs) to use simvastatin was
approximately twice that of lovastatin/extended-release
niacin ($665 versus $332). CONCLUSIONS: For LDL
goals <130 and <100mg/dL (and HDL ≥40mg/dL), lovas-
tatin/ extended-release niacin was both more successful
and less costly than simvastatin.
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DETERMINANTS OF COST EFFECTIVENESS IN
CLINICAL GUIDELINES FOR CARDIOVASCULAR
PROPHYLAXIS WITH STATINS
Milne RJ, Gamble GD
University of Auckland, Auckland, New Zealand
OBJECTIVES: To quantify the major determinants of
population cost effectiveness of clinical guidelines for risk
screening and prevention of cardiovascular disease (CVD)
with “statin” therapy. METHODS: Risk proﬁles were
collected for 4704 men age 35–84y and 1216 women age
45–84y without CVD. 5-year risk of a cardiovascular
hospital admission for each individual was calculated
using a Framingham risk equation. The predicted number
of incident events in 5 years was scaled by age and gender
to the 2001 NZ census population and integrated over
age groups. Costs, beneﬁts and cost effectiveness were
estimated at treatment thresholds Tc/HDLc = 4.0 to 6.5
and 5y risk 10% or 15%; and screening age thresholds
35/45 (M/F) to 50/60y and treatment adherence 50% to
84%. RESULTS: In the NZ population of 784K men age
35–84y and 558K women age 45–84y, at treatment
thresholds of Tc/HDLc = 5.5 and 15% 5y risk, 56K men
and 20K women would be eligible for prophylaxis. 
Compared to no intervention, 5y prophylaxis with 84%
adherence would avert 3875 incident cardiovascular
events and add 3712 life years at an incremental cost of
$NZ29M and ICER < $NZ8000 ($US4000) per event
avoided or LYG (discounted at 5%). The ICERs change
2 to 3-fold with treatment adherence (50% vs 84%),
threshold lipid ratio (4.5 or 6.5 vs 5.5) and threshold
screening age (50/60 vs 35/45) but less than 25% with
treatment efﬁcacy (24% vs 30%) and the 5y risk treat-
ment threshold (10% vs 15%). The cost per LYG also
depends strongly on the 5y cardiovascular fatality rate
and the discount rate. CONCLUSIONS: Prophylaxis
with ‘statins’ is very cost effective at current drug prices
and clinically realistic treatment thresholds. Clinical
guidelines for cardiovascular prophylaxis should focus on
the threshold age for risk screening, the threshold lipid
ratio and methods for enhancing treatment adherence.
PCV35
COST EFFECTIVENESS ANALYSIS OF HMG-COA
REDUCTASE INHIBITORS IN A MEDICAID
POPULATION
MacLean EA, Mofﬁtt CM
Pﬁzer, Inc, Wakeﬁeld, RI, USA
OBJECTIVES: This retrospective analysis of publicly
available pharmacy claims data evaluates prescription
trends and estimates cost effectiveness of statins based 
on acquisition cost and LDL-C lowering capacity.
METHODS: Massachusetts Medicaid statin utilization
data for 2001 was obtained from the Centers for
Medicare and Medicaid (CMS) website (www.cms.gov/
medicaid/drugs/drug5.htm). Units per prescription,
average cost per prescription, marketshare, days supply,
and average cost per day were calculated. The annual cost
per percent LDL-C reduction was calculated by dividing
the annual cost by the percent LDL lowering capacity.
These methods modeled the CURVES study and a subse-
quent pharmacoeconomic analysis by Hilleman, et al.
LDL-C lowering capacity was obtained from the package
insert for drug strengths not studied in the CURVES
study. Drugs were compared based on equipotent LDL-C
lowering capacity. Acquisition costs were not reﬂective of
manufacturer rebates. RESULTS: The statin market was
comprised of atorvastatin at 67.33%, simvastatin at
14.76%, pravastatin at 10.74%, lovastatin at 3.91% and
ﬂuvastatin at 3.25%. Atorvastatin 10mg, the most com-
monly prescribed agent (40.02%), was the most cost
effective agent with an annual patient cost per percent
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LDL-C reduction of $17.12. In comparison, the costs 
per percent LDL-C reduction for equipotent strengths of
other statins were ﬂuvastatin 80mg at $17.93, simvas-
tatin 20mg at $36.84, pravastatin 40mg at $37.66 and
lovastatin 40mg at $47.29. Acquisition costs per unit for
these agents were $1.78, $1.72, $3.53, $3.51 and $4.02,
respectively. CONCLUSION: Acquisition cost is one
component in evaluating cost of therapy. However, in this
analysis, among equipotent agents, the agent with the
lowest acquisition cost was not the most cost effective.
Attempts to quantify cost effectiveness should be made
when reviewing the statin class.
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COST-EFFECTIVENESS OF TREATING BY
SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK
PATIENTS: AN ECONOMIC EVALUATION BASED
ON THE HEART PROTECTION STUDY
Fagnani F1, Lafuma A2, Souchet T3
1CEMKA, Bourg la Reine, France; 2CEMKA-EVAL, Bourg La
Reine, France; 3Merck Sharp & Dohme–Chibret, Paris, France
OBJECTIVES: Estimate the cost-effectiveness ratio in
France of treating high vascular risk patients with sim-
vastatin. METHODS: Data on efﬁcacy and resources
consumed were extracted from the published results of
the MRC/BHF Heart Protection Study (HPS) performed
in UK. HPS compared the occurrence of total and CHD
deaths, major vascular events (MVE), and major coro-
nary events (MCE) in more than 20,000 patients with
high vascular risk (patients with diabetes, history of
stroke or other cerebrovascular disease, peripheral arter-
ial disease, or with CHD). Patients were randomly
assigned to receive simvastatin or placebo and followed
at least for ﬁve years. The cost-effectiveness analysis was
performed using French unit costs. The survival beneﬁt
over the study period was estimated from the HPS results.
Direct costs included the extra costs of simvastatin and
the beneﬁt associated with avoided vascular events. Indi-
rect costs were not considered. Costs and beneﬁt were
discounted at 5%. RESULTS: All-cause mortality was
reduced by 13% (RR = 0.87, p = 0.0003). There was a
discounted survival beneﬁt of 0.040 year per included
patient. There were highly signiﬁcant reductions of about
one quarter in the risk of ﬁrst event rate of MVE (RR =
0.76, p < 0.0001) and of MCE (RR = 0.73, p = 0.0001).
The absolute value of the percentage of avoided event
during the 5-year period in the simvastatin group was
5.4% for any major vascular event, 2,1% for non fatal
MI, 1.3% for non fatal stroke, 2.4 % for revascularisa-
tion, 1.2% for fatal MI and 0.2% for fatal stroke. The
discounted extra cost of simvastatin was estimated at
€1994 ($1 = €1) taking into account the statins used in
the placebo group. This cost was reduced to €1031 by
considering the direct cost associated with avoided vas-
cular events. Cost-effectiveness ratio was then estimated
at €23,678 per life year gained (€22,000 to €50,000 
in the different subcategories of patients, ratios well
accepted as being cost-effective). CONCLUSIONS: Treat-
ment with simvastatin in different subcategories of
patients with high vascular risk is cost-effective in the
French setting.
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BASELINE PREDICTORS OF ONE-YEAR COSTS
AFTER ACUTE MYOCARDIAL INFARCTION IN
THE ELDERLY
Liao L1, Bundorf MK2, Kauf T3, Schulman KA1,Whellan D4,
Jollis J1
1Duke University Medical Center, Durham, NC, USA;
2Stanford University, Stanford, CA, USA; 3Duke University,
Durham, NC, USA; 4Duke Clinical Research Institute, Durham,
NC, USA
OBJECTIVES: Studies examining costs following
myocardial infarction (MI) have been limited by short
follow-up, small sample sizes, restricted patient popula-
tions, or failure to include hospital, physician, or market
characteristics. In a national sample with extensive sup-
plemental data, we sought to identify the baseline factors
predicting higher costs in the year following MI.
METHODS: Elderly acute MI patients totaling 84,373
(90% white, 49% female) in the Cooperative Cardiovas-
cular Project were linked to Medicare Part A claims, AHA
Hospital Surveys, the CMS directory of physician spe-
cialties, and the CMS Hospital Wage Index File. Medicare
charges were converted to costs using institutional cost to
charge ratios. Associations with admission episode and
one-year log-transformed costs were assessed by regres-
sion analysis with robust standard errors. RESULTS:
Mean cost was $12,956 (median $8,833) for the admis-
sion episode and $19,597 (median $13,583) at one year.
Patient characteristics accounted for 11% of the admis-
sion and one-year cost variation. Patient variables most
highly associated with one-year costs included anterior
MI, CHF, COPD, renal insufﬁciency, diabetes, and shock.
Older age (age 80 years) was most strongly associated
with lower costs. After adding hospital, physician, and
market variables, the models explained 22% of admission
and 17% of the one-year cost variation. Teaching hospi-
tals and care by a cardiologist were both associated with
higher one-year costs. While patient death was associated
with lower admission episode costs, death after the initial
episode was associated with higher one-year costs. CON-
CLUSION: In models examining the baseline predictors
of one-year costs following MI, patient characteristics
account for approximately twice the cost variation
accounted for by other baseline variables.
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A COST AND COST-EFFECTIVENESS (CE)
ANALYSIS OF ANGIOTENSIN CONVERTING
ENZYME (ACE) INHIBITOR TRANDOLAPRIL IN
THE TREATMENT OF POST INFARCTION IN
THE US
Lilliu H1, Le Pen C1, Lamiraud K1,Wittenberg W2
1Clp-santé, Paris, France; 2Abbott GmbH & Co KG,
Ludwigshafen, Germany
